Zimmer (ZBH) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Core Insights - Zimmer Biomet reported $1.91 billion in revenue for the quarter ended March 2025, reflecting a year-over-year increase of 1.1% and an EPS of $1.81 compared to $1.94 a year ago, with revenue exceeding the Zacks Consensus Estimate of $1.89 billion by +0.88% and an EPS surprise of +2.84% [1] Revenue Performance - Net Sales for Knees in the United States were $459 million, slightly below the average estimate of $464.68 million, representing a year-over-year change of +0.2% [4] - Net Sales for Hips in the United States reached $264.30 million, surpassing the average estimate of $258.29 million, with a year-over-year increase of +3.7% [4] - International Net Sales for Hips were $231.50 million, slightly above the average estimate of $229.39 million, showing a year-over-year decline of -2% [4] - International Net Sales for Knees were $333.90 million, exceeding the average estimate of $328.76 million, with a year-over-year increase of +1.2% [4] - Total International Net Sales amounted to $795.50 million, surpassing the estimated $783.50 million, reflecting a +0.7% change year-over-year [4] - Total Net Sales in the United States were $1.11 billion, slightly above the estimated $1.10 billion, indicating a +1.3% year-over-year change [4] - Overall Net Sales for Knees were $792.90 million, exceeding the average estimate of $787.14 million, with a year-over-year increase of +0.6% [4] - Net Sales for Other products were $149.90 million, below the average estimate of $152.71 million, representing a year-over-year decline of -4.7% [4] - Net Sales for S.E.T. reached $470.50 million, surpassing the average estimate of $460.26 million, with a year-over-year increase of +4% [4] - Net Sales for Hips totaled $495.80 million, exceeding the average estimate of $488.84 million, reflecting a +0.9% year-over-year change [4] Stock Performance - Zimmer's shares have returned -4.6% over the past month, contrasting with the Zacks S&P 500 composite's +0.4% change, and the stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market [3]